TrialCancer2019

Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: Implications for risk-based therapeutic intensity trials.

Carole Fakhry et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.